Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
96.22
+0.93 (0.98%)
Oct 20, 2026, 10:30 AM EDT - Market open
Insmed Employees
Insmed had 1,664 employees as of December 31, 2025. The number of employees increased by 393 or 30.92% compared to the previous year. That makes Insmed the 11,431st largest employer in the world and 1,848th in the United States.
Employees
1,664
Change (1Y)
393
Growth (1Y)
30.92%
Revenue / Employee
$683,675
Profits / Employee
-$526,028
Market Cap
21.01B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,664 | 393 | 30.92% |
| Dec 31, 2024 | 1,271 | 359 | 39.36% |
| Dec 31, 2023 | 912 | 176 | 23.91% |
| Dec 31, 2022 | 736 | 123 | 20.07% |
| Dec 31, 2021 | 613 | 92 | 17.66% |
| Dec 31, 2020 | 521 | 86 | 19.77% |
| Dec 31, 2019 | 435 | 62 | 16.62% |
| Dec 31, 2018 | 373 | 159 | 74.30% |
| Dec 31, 2017 | 214 | 53 | 32.92% |
| Dec 31, 2016 | 161 | 36 | 28.80% |
| Dec 31, 2015 | 125 | 36 | 40.45% |
| Dec 31, 2014 | 89 | 28 | 45.90% |
| Dec 31, 2013 | 61 | 20 | 48.78% |
| Dec 31, 2012 | 41 | -1 | -2.38% |
| Dec 31, 2011 | 42 | 2 | 5.00% |
| Dec 31, 2010 | 40 | 25 | 166.67% |
| Dec 31, 2009 | 15 | -82 | -84.54% |
| Dec 31, 2008 | 97 | 3 | 3.19% |
| Dec 31, 2007 | 94 | -63 | -40.13% |
| Dec 31, 2006 | 157 | 72 | 84.71% |
| Dec 31, 2005 | 85 | 30 | 54.55% |
| Dec 31, 2004 | 55 | 35 | 175.00% |
| Dec 31, 2003 | 20 | -3 | -13.04% |
| Dec 31, 2002 | 23 | -37 | -61.67% |
| Dec 31, 2001 | 60 | 20 | 50.00% |
| Dec 31, 2000 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 7,807 |
| Genmab | 3,119 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| Ascendis Pharma | 1,189 |
| Exelixis | 1,077 |
| BridgeBio Pharma | 1,003 |
INSM News
- 1 hour ago - Insmed price target lowered to $173 from $187 at Raymond James - TheFly
- 3 hours ago - Insmed Appoints Two New Directors to Its Board - PRNewsWire
- 1 day ago - Insmed announces commercial launch of brinsupri tablets in Japan - TheFly
- 1 day ago - Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan - PRNewsWire
- 4 days ago - Roth Capital healthcare analysts hold analyst/industry conference call - TheFly
- 5 days ago - Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026 - PRNewsWire
- 6 days ago - Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026 - PRNewsWire
- 8 days ago - Insmed price target lowered to $207 from $214 at BofA - TheFly